Processing Magazine
  • Subscribe
  • Magazine
  • Events
  • News & Notes
  • Videos
  • Podcasts
  • Webinars
  • White Papers
  • 3D Models
  • Breakthrough Products Awards
  • Maintenance & Safety
  • Material Handling
  • Mixing & Blending
  • Powder & Bulk Processing
  • Process Control & Automation
  • Pumps, Motors & Drives
  • Valves & Actuators
  • Topics
    Maintenance & SafetyMaterial HandlingMixing, Blending & Size ReductionProcess Control & AutomationPumps, Motors & DrivesValves & ActuatorsPowder & Bulk Solids
    Resources
    MagazineEventsNews & NotesVideosPodcastsWebinarsWhite PapersBreakthrough Products Awards
    User Tools
    SubscribeAdvertiseAbout UsContact UsPrivacy PolicyTerms & Conditions
    http://www.facebook.com/ProcessingMagazine
    https://www.linkedin.com/showcase/27062974
    https://twitter.com/ProcessingMag
    1. Maintenance & Safety
    2. Standards & Regulations

    FDA takes action against Indian pharmaceutical companies

    June 3, 2013

    Pharmaceutical company Hospira Inc. has been warned by the U.S. Food and Drug Administration (FDA) over lapses in the manufacturing of drugs, which were detected during an inspection of its facility in Irungattukottai, India, in October 2012.

    Staff
    drug manufacturing
    drug manufacturing
    Ts 139472022
    FDA inspectors found that surfaces at the facility were not properly sanitized and aseptic manufacturing intervention was not performed. Photo credit: Harald Richter/Getty Images/iStockphoto

    Pharmaceutical company Hospira Inc. has been warned by the U.S. Food and Drug Administration (FDA) over lapses in the manufacturing of drugs, which were detected during an inspection of its facility in Irungattukottai, India, in October 2012.

    The warning letter sent to the company stated that unless the manufacturing processes at the facility were improved so that they complied with regulations, drugs produced at the plant may be denied access to the United States. The company announced that the FDA warning letter referred to breaches of quality regulations for finished drugs.

    FDA inspectors found that surfaces at the facility were not properly sanitized and aseptic manufacturing intervention was not performed. Moreover, during the inspection, employees did not always wear gloves when handling products, which suggested that the production may not have been sterile, as required. Unless adequate assurance of their sterility could be provided, products cannot enter the U.S. market, the agency explained. It demanded that Hospira provided an action plan to correct the failings and to prevent further substandard manufacturing over the next 30 days.

    A spokesman for the company stated that Hospira was currently reviewing the warning letter and the recommendation made by FDA inspectors, but pointed out that the letter was not likely to result in dramatic changes to the scope or timing of the company's remediation efforts at IKKT or to affect other pharmaceutical manufacturing plants. He added that Hospira was taking the matter seriously and planned to do whatever possible to respond in detail to the letter within the allowed timeframe.

    RELATED: Chinese pharma businesses eye international markets

    In March 2010, Hospira agreed to buy the facility from Orchid Chemicals, a producer of generic injectable finished dosage drugs. The plant manufactures beta-lactam antibiotic formulations manufacturing complex (comprising cephalosporin, penicillin and carbapenem facilities). ? pharmaceutical research and development facility is also situated at the same site. Hospira has been struggling to comply with regulations on multiple occasions at its manufacturing plants since 2010.

    Meanwhile, it emerged that Hospira was not the only Indian drug producer that has been under scrutiny. The FDA has also kept a close eye on generic drug makers Ranbaxy and Wockhardt, which also market drug products for use in the United States. The U.S. Department of Justice reached an agreement with Ranbaxy, with the company having to pay $500 million in civil and criminal fines. The drug manufacturer pleaded guilty to three accounts related to the production of drugs at two Indian facilities. The FDA found that the company violated regulations regarding a series of malpractices and data manipulation. The Times of India revealed that before the FDA took any action, Ranbaxy had been warned that it needed to improve its systems and elect to be controlled by external auditors.

    The other drug maker, Wockhardt, received an import alert on products manufactured at a plant in Maharashtra. The import alert is practically a ban that leads to detention without the physical examination of drugs produced at the facility in question. The company estimated that the ban would hit its revenues and cause the potential loss of $100 million this year but it would try to mitigate the effect by moving part of its production to other facilities.

    Continue Reading

    Making remote support work in manufacturing

    Choosing the right AODD pump can help decrease energy consumption

    Sponsored Recommendations

    Yokogawa and FPT Software ink global partnership to advance DX solution offerings

    The partnership will help accelerate the growth of Yokogawa's DX portfolio of applications and services while helping FPT Software expand its market reach. The agreement is in...

    Efficient pressure compensation improves weighing accuracy in loss-in-weight feeders

    Electronic pressure compensation systems are more effective and reliable than traditional mechanical systems.

    In Processing Ep. 4: Dust collection basics for powder and bulk solid applications

    Jacques Kregting, a senior application engineer for RoboVent, writes about how dust collection solutions must be tailored to the characteristics of the dust, the requirements ...

    How AIoT is reshaping the process industries

    The benefits, use cases and future predictions of transformation for this powerful new tool.

    Latest in Standards & Regulations

    ID 227746257 © Rafael Henrique | Dreamstime.com
    Dreamstime Xxl 227746257
    Standards & Regulations

    Heads up: NFPA 660 Standard for Combustible Dusts is coming

    Jack Osborn
    Aug. 22, 2023
    Photo 101382116 © Péter Gudella | Dreamstime.com
    Dreamstime M 101382116
    Standards & Regulations

    Why product carbon footprint matters — and 3 steps to better measure and manage it

    Marko Lange
    July 28, 2022

    Most Read

    Process Expo 2023 promises a host of new experiences, opportunities and excitement

    Spark detection and extinguishing system

    Distributed control system

    Sponsored Recommendations

    Yokogawa and FPT Software ink global partnership to advance DX solution offerings

    Efficient pressure compensation improves weighing accuracy in loss-in-weight feeders

    In Processing Ep. 4: Dust collection basics for powder and bulk solid applications

    Processing Magazine
    http://www.facebook.com/ProcessingMagazine
    https://www.linkedin.com/showcase/27062974
    https://twitter.com/ProcessingMag
    • About Us
    • Contact Us
    • Advertise
    • Do Not Sell or Share
    • Privacy Policy
    • Terms & Conditions
    © 2023 Endeavor Business Media, LLC. All rights reserved.
    Endeavor Business Media Logo